Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

hospira, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0 - potassium chloride 1.79 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw need

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 50 mg in 5 ml - initial  treatment  of  advanced  ovarian  carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary  treatment  of  advanced  ovarian  carcinoma carboplatin injection is indicated for the palliative treatment of patient

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sanja pharmaceuticals company - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 50 mg in 5 ml - initial treatment of advanced ovarian carcinoma carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin injection and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin, usp vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. secondary treatment of advanced ovarian carcinoma carboplatin injection is indicated for the palliative treatment of pati

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sandoz inc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with c

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 10mmol/500ml) / glucose 4% / sodium chloride 0.18% infusion 500ml bags (baxter healthcare ltd - potassium chloride; glucose anhydrous; sodium chloride - infusion - 1.5mg/1ml ; 40mg/1ml ; 1.8mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 10mmol/500ml) / sodium chloride 0.9% infusion 500ml viaflo bags (baxter healthcare ltd - potassium chloride; sodium chloride - infusion - 1.5mg/1ml ; 9mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/500ml) / sodium chloride 0.9% infusion 500ml viaflo bags (baxter healthcare ltd - potassium chloride; sodium chloride - infusion - 3mg/1ml ; 9mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/1litre) / glucose 5% infusion 1litre viaflo bags (baxter healthcare ltd - potassium chloride; glucose anhydrous - infusion - 1.5mg/1ml ; 50mg/1ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

fresenius kabi usa, llc - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus  cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously t

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - carboplatin 10 mg/ml;  ;   - solution for injection - 10 mg/ml - active: carboplatin 10 mg/ml     excipient: nitrogen water for injection